What's Happening?
Ollin Biosciences has announced positive topline results from its Phase 1b JADE clinical study, which compared OLN324, a next-generation VEGF/Ang2 bispecific antibody, to faricimab in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The study demonstrated that OLN324 provided faster and greater improvements in retinal drying and vision gains compared to faricimab. Nearly 90% of DME patients treated with OLN324 achieved absence of disease at 12 weeks, compared to 57% of those treated with faricimab. The company plans to initiate global Phase 3 trials in 2026.
Why It's Important?
The promising results of OLN324 suggest it could become a new standard of care in the $15 billion market for retinal therapeutics. The drug's ability
to achieve faster and more significant retinal drying and vision improvements positions it as a potentially superior treatment option for DME and wAMD. This development is significant for patients suffering from these vision-threatening conditions, as it offers hope for more effective management and improved quality of life. The success of OLN324 could also enhance Ollin Biosciences' position in the competitive ophthalmology market.
What's Next?
Ollin Biosciences plans to discuss the JADE study results and its future pipeline at the upcoming J.P. Morgan Healthcare Conference. The company is preparing to move OLN324 into global Phase 3 trials, which will further evaluate its efficacy and safety. The full results of the JADE study will be presented at the Angiogenesis, Exudation, and Degeneration symposium in February 2026. These steps will be crucial in determining OLN324's potential as a leading treatment for retinal diseases and its impact on the market.
